Biosimilar Manufacturer Reliability Is Key To Market Uptake, Amgen Says
This article was originally published in The Pink Sheet Daily
Executive Summary
In its latest biosimilar trends report, Amgen makes the case for purchasing biosimilars from a company with a track record for quality biologics manufacturing – presumably, one such as its own.